Echoiq Limited · ASX:EIQ
Echoiq — Investor Presentation (May 2023)
17 slides from Echoiq's investor presentation, May 11, 2023
Slide 1: Echo iQ: AI-backed Cardiology Support
Echo iQ Al-backed Cardiology Support Artificial Intelligence proven to enhance detection of structural heart disease ASX:EIQ Company Presentation: 11 May 2023 Ali wit YY hheert
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This presentation has been prepared by ECHOIQ LIMITED "EIQ". This document contains background information about EIQ current at the date of this presentation, 11 May 2023. The presentation is in summary form and does not purport to be all inclusive or comple
Slide 3: EchoSolv identified every case of severe aortic stenosis
In a recent clinical study, Echo 1Q’s EchoSolv™ technology was shown to accurately identify every single case of severe aortic stenosis. This represents a (2% improvement versus human-only diagnosis.
Slide 4: Corporate Snapshot
Corporate Snapshot 439,296,/97 Shares on issue A$0.145 Share Price (11.05.2023) A$63.7M Market Capitalisation A$2,649,000 Cash toa Term Beet (31.03.2022) SHAREHOLDER BREAKDOWN a Board of Directors Other as & Top 20 Shareholders > Disciplined approach to managing cash and shareholder dilution BOARD O
Slide 5: The Problem
The Problem of all deaths worldwide people with heart valve Mortality rate for untreated attributed to disease don’t know they symptomatic severe cardiovascular disease i have got it H aortic stenosis > Aortic Stenosis (AS) occurs when the heart’s aortic valve > It has a mortality rate worse than ma
Slide 6: Aortic Stenosis
Aortic Stenosis cost EchoiQ WHEN MISDIAGNOSED: $4.6B in annual healthcare costs for untreated AS” Costly unplanned admissions - ~11 days spent in hospital each year when untreated® Lost revenue to hospitals and cardiologists as few procedures performed WHEN DIAGNOSED: Fewer unplanned admissions ~1 d
Slide 7: EchoSolv
EchoSolv SCIENTIFICALLY PROVEN Al - For enhancing diagnosis of aortic stenosis EchoSolv™ removes the labour intensity, user dependency and unconscious bias resulting in far greater accuracy of diagnosis compared to traditional methods Echo iQ Automated Al and machine learning based assessment delive
Slide 8: Our Competitive Moat
Echo iQ Our Competitive MOAT m=, BACKED BY HQ] carpiac Bic pata > Exclusive Al access to National Echo Database of Australia (NEDA) echo measurement data (world’s largest) > Mortality linked data an added source of differentiation > Trained on 200M echo data endpoints CLINICALLY VALIDATED > US Study
Slide 9: Rapid progress since acquisition
Rapid progress since acquisition 22022 Q3 2022 Q4 Q1 2023 y v ’ ’ y FDA Strategy Advisory Board EchoSolv™ Launch US Team Growth Maiden Revenues + Strategy defined + Leading experts in + Platform for AS + President + Australian cardiology + 510(k) global cardiology launched + Marketing practice + AHA
Slide 10: Proven clinical effectiveness
Proven clinical effectiveness BW sezearo urn sooo. GY Feicunoosrrat EchoSolv™ identified 100% of the patients with EchoSolv™ identified 100% of the patients with guideline-defined severe aortic stenosis, equal to ~5% guideline-defined severe aortic stenosis, equal to ~4% of the study population. of
Slide 11: Commercialisation
Commercialisation US Market Focus* ce + TOP 10 Healthcare States + Hospitals/ASCs + Cardiology Clinics + Leading agent appointed (Cassling Diagnostic) FOCUS MARKETS Echo iQ Selected Additional <~ Markets* + Australia (Hydrix Medical appointed re-seller) * Advanced stage discussions underway Refer to
Slide 12: Potential to deliver meaningful financial impact
Potential to deliver meaningful financial impact Human Diagnosis Human Diagnosis <i dlliiadie~ : g * eae + EchoSolv 218 — ees E376 Saa2” US$6.98M-~ "sere" --US$9.84M-- + 41% “Extrapolated figures derived using exact figures from St. Vincent's Clinical Study combined with assumed industry replacement
Slide 13: 510K FDA clearance pathway
510K FDA clearance pathway Securing FDA Clearance in US market Allows cardiologists and hospitals to pursue undiagnosed patients and tap becomes a material revenue accelerator revenue from insurance and public health rebate channels (similar to Medicare) Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Pre-s
Slide 14: Scientific Advisory Board
Scientific Advisory Board > Comprises a team of globally recognised Prof. Huon H. Gray, Partho Sengupta James Thomas, + + di | di : CBE MD MD MBBS FACC FASE MD MD FACC FASE FESG Oxpells IN Calne Former National Cical Director CVD, NHS Henry Rutgers Professor of Cardlology Former President Am. Societ
Slide 15: Catalysts for growth
Catalysts for growth LEVERAGE KEY INDUSTRY PARTNERSHIPS + MedAxiom for direct engagement with US interventional cardiology market + Hydrix Medical for Australian market penetration + Cassling Diagnostic Imaging for US Mid-West market penetration EXECUTE DEFINED FDA STRATEGY + Successful completion o
Slide 16: References
References 1 https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) 2 https://hopeforhearts.com.au/aortic-stenosis/ 3 https://emedicine.medscape.com/article/150638-overview#:~:text=Among %20symptomatic% 20patients%20with %20medically, period %200f%2010%2D20%20years. 4 Nathan
Slide 17: AI with heart
AI with heert www.echoiq.ai